Docoh
Loading...

EMMA Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. It engages in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. The company is headquartered in Torrance, CA.

Company profile

Ticker
EMMA, EMMAW
Exchange
CEO
Yutaka Niihara
Employees
Incorporated
Location
Fiscal year end
Former names
AGE RESEARCH INC, CNS RESPONSE, INC., MYnd Analytics, Inc., SalesTactix, Inc., STRATIVATION, INC.
SEC CIK
IRS number
870419387

EMMA stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Sep 18 Sep 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.59 500 795 10,765,871
21 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.59 1,250 1.99K 10,765,371
18 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.59 500 795 10,764,121
16 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.6 500 800 10,763,621
15 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.6 1,990 3.18K 10,763,121
14 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.6 1,416 2.27K 10,761,131
11 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.58 800 1.26K 10,759,715
10 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.65 1,000 1.65K 10,758,915
8 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.61 1,000 1.61K 10,757,915
7 Jun 21 Niihara Yutaka Common stock, $0.001 par value Buy Aquire P No No 1.55 500 775 10,756,915

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 1 EXIT
Opened positions 0 0
Closed positions 1 0 NEW
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Proequities 0 0

Financial report summary

?
Risks
  • We have operated at a loss and may continue to operate at a loss for the foreseeable future.
  • We are dependent on the commercial success of our only approved product, Endari®.
  • There are uncertainties related to our working capital and we may need to raise additional financing.
  • The COVID-19 pandemic may adversely affect our revenues, results of operations and financial condition and impact our ability to obtain needed financing.
  • We may expend our limited resources to pursue a product candidate or indication and fail to capitalize on product candidates or indications for which there is a greater likelihood of commercial success.
  • We face intense competition from companies with greater resources than us, and if our competitors are successful in marketing or develop alternative treatments our commercial opportunities may be reduced or eliminated.
  • If we are unable to achieve and maintain adequate levels of coverage and reimbursement for Endari®, on reasonable pricing terms, its commercial success may be severely hindered.
  • The majority of Endari® sales are to a few customers and loss of a customer could adversely affect our results of operations.
  • The market exclusivity for Endari® for SCD is limited, which could adversely affect our ability to compete in the market and adversely affect the commercial success of Endari®.
  • Many of our potential customers are in markets with underdeveloped health care systems.
  • A variety of other risks associated with marketing any of our products internationally could hurt our business.
  • We may not be able to anticipate the demand for and appropriate supply of Endari®.
  • If the L-glutamine manufacturers upon which we rely fail to produce in the volumes and quality that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical manufacturers, we may face interruptions in the commercialization of, or be unable to meet demand for, our L- glutamine based products, and may lose any marketing exclusivity and potential revenues.
  • We expect to rely on third parties to conduct future clinical trials of our product candidates and those third parties may not perform satisfactorily, including failing to meet deadlines for the conduct of such trials.
  • Endari® may cause undesirable side effects or have other unexpected properties that could result in post-approval regulatory action.
  • We face potential product liability exposure relating to Endari® and, if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
  • The use of any of our product candidates in clinical trials and in the market may expose us to liability claims.
  • We will need to increase the size and complexity of our organization in the future, and we may experience difficulties in managing our growth and executing our growth strategy.
  • We will need to attract and retain sufficient talented employees and scientific collaborators.
  • We rely heavily on Yutaka Niihara, M.D., M.P.H., our Chairman and Chief Executive Officer, and the loss of his services would have a material adverse effect upon our business and prospects.
  • Our business and operations may be adversely affected by information technology (“IT”) system failures or cybersecurity or data breaches.
  • We have identified material weaknesses in our internal controls over financial reporting.
  • We may not be able to obtain and enforce intellectual property rights that cover our commercial activities or are sufficient to prevent third parties from competing against us.
  • We depend on licenses and sublicenses of certain patents. If any of these licenses, sublicenses, or the licenses under which we have been sublicensed terminates, or if any of the patents that have been licensed or sublicensed to us is challenged and we are limited in our ability to utilize any of those patents, we may be unable to develop, out-license, market and sell our products, which would cause a material adverse effect on our business, prospects, financial condition, and operating results.
  • If we are unable to protect proprietary technology that we invent and develop, we may not be able to compete effectively, and our business and financial prospects may be harmed.
  • Endari® is subject to ongoing and continued regulatory review, compliance with which may result in significant expense and limit our ability to commercialize Endari®.
  • We may not be able to receive regulatory approval for our prescription grade L-glutamine treatment for diverticulosis or other indications, which would adversely affect our financial and operating condition.
  • The development process to obtain FDA approval for new drugs therapies is very costly and time consuming and if we cannot complete our clinical trials in a cost-effective manner, our operations may be adversely affected.
  • We may not be able to complete clinical trial programs for any of our product candidates successfully within any specific time period or at all, and if such clinical trials take longer to complete than we project, our ability to execute our current business strategy will be adversely affected.
  • We may be required to suspend, repeat or terminate our clinical trials if they do not meet regulatory requirements, the results are negative or inconclusive, human subject protections are inadequate, the trials are not well designed, or clinical investigators fail to comply with all requirements for the conduct of trials under the applicable IND, any of which may result in significant negative repercussions on our business and financial condition.
  • Changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary changes to clinical trial protocols, informed consents and clinical trial budgets, any of which changes could result in increased costs to us, delay our development timeline or reduce the likelihood of successful completion of the clinical trial.
  • There are various uncertainties related to the research, development and commercialization of the cell sheet engineering regenerative medicine products we are developing in collaboration with a strategic partner which could negatively affect our ability to commercialize such products.
  • Health care reform measures and changes in policies, funding, staffing and leadership at the FDA and other agencies could hinder or prevent the commercial success of Endari®.
  • If we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.
  • Even though we have obtained Orphan Drug designation for Endari®, we may not be able to maintain Orphan Drug marketing exclusivity for this product candidate or any of our other product candidates.
  • Any product candidate for which we obtain marketing approval would be subject to post-marketing regulatory requirements and limitations and could be subject to recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with such regulatory requirements or if we experience unanticipated problems in commercializing any of our product candidates, when and if any of them are approved by regulators.
  • Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of our product candidates and then commercialize them as products and affect the prices we may obtain.
  • EJ Holdings has no revenues and is dependent on us to fund its business and operations, and there is no assurance that we can continue to provide needed funding or that EJ Holdings will be able to continue its activities.
  • EJ Holdings is subject to risks inherent in a new business and may not be successful.
  • We do not control EJ Holdings, and EJ Holdings may engage in activities contrary to our best interests.
  • EJ Holdings retains discretion over its use of any funds that we provide to it.
  • We have been delinquent in our SEC reporting obligations, which has adversely affected the ability of our security holders and prospective investors to have current information regarding our financial statements and status of our business and operations and could lead to the disqualification of our common stock for quotation on the OTC Markets Group, Inc.
  • We have experienced, and may continue to experience, significant volatility in our stock price.
  • Trading on the OTC Markets is volatile and sporadic, which could depress the market price of our common stock and make it difficult for our security holders to resell their common stock.
  • Stockholders may experience future dilution as a result of future equity offerings.
  • A substantial number of shares of common stock may be sold in the market, which may depress the market price for our common stock.
  • Out common stock is not traded on a national securities exchange, which may adversely affect our ability to raise needed financing.
  • As long as our common stock is quoted on the OTC Markets, our stockholders may face significant restrictions on the resale of our common stock due to state “blue sky” laws.
  • We may issue preferred stock in the future, and the terms of the preferred stock may reduce the value of our common stock.
Management Discussion
  • Net Income (Loss). Net income was $1.1 million for the year ended December 31, 2020 compared to a net loss of $54.8 million for the year ended December 31, 2019, representing an increase of $55.9 million, or 102%. The increase in net income was primarily a $50.9 million increase in other income, and a $5.2 million decrease in operating expenses, as discussed below. As of December 31, 2020, we had an accumulated deficit of approximately $225.3 million. Our net income for the year ended December 31, 2020 included approximately $2.3 million of losses attributable to our equity interest in EJ Holdings, a variable interest entity, or VIE. Our independent registered public accounting firm was unable to obtain audited financial statements or other audit support for such losses as described in Note 5 to Notes to Financial Statements included in this Annual Report. As a result, their audit report included in this Annual Report contains a qualification in this regard. The losses attributable to our equity interest in EJ Holdings for the year ended December 31, 2019 were insignificant.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: ab, absent, ample, Arab, bode, branch, caption, constant, contraindication, deadline, delinquent, deposit, differentiated, FINRA, floor, ingredient, intolerance, investee, IRS, le, mathematical, Merton, Michigan, NaN, prepay, Prestige, progression, pyrogen, recalculating, rollout, shelf, Sherwood, switched, thousand, treatable, unilateral, upper, vaccine
Removed: advice, afforded, alternatively, amortization, asserted, asserting, assessing, assisting, bid, broadly, considerable, consult, contracting, controlling, curtail, decide, default, defending, description, disadvantage, disclosing, document, effected, eliminate, employer, facilitating, favorable, fine, footnote, forming, FTC, identification, illegal, impede, imprisonment, kind, la, ordered, overpayment, partnering, personally, prohibited, qui, reexamination, released, replace, requisite, resume, reward, Robin, role, satisfaction, Smith, spent, supplemented, symbol, tam, treble, USA, violate, waived, whistleblower, willfully, writing